FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid TumorsLeigh Marcus, Steven J. Lemery, Lisa Rodríguez et al.|Clinical Cancer Research|2021Cited by 567
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of ChemotherapyGeoffrey Kim, Richard Pazdur, Gwynn Ison et al.|Clinical Cancer Research|2015Cited by 526